SAB Biotherapeutics (SABS, Financial) has seen a positive development as H.C. Wainwright initiates coverage with a Buy rating and sets a $10 price target. This optimistic outlook follows the release of encouraging results from SAB-142 trials. The trials, conducted on healthy volunteers, revealed durable immunomodulation effects along with a favorable safety profile. These findings suggest that SAB-142, a human anti-thymocyte immunoglobulin, could become a promising new immunotherapy aimed at preventing and managing type 1 diabetes progression.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for SAB Biotherapeutics Inc (SABS, Financial) is $9.00 with a high estimate of $12.00 and a low estimate of $7.00. The average target implies an upside of 379.49% from the current price of $1.88. More detailed estimate data can be found on the SAB Biotherapeutics Inc (SABS) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, SAB Biotherapeutics Inc's (SABS, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
